Orthopaedic & Rheumatologic Institute Outcomes
Surgical Quality Improvement
Total Hip Arthroplasty Outcomes
Total Hip Arthroplasty ACS NSQIP Outcomes
January 1, 2023 – December 31, 2023
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall total hip arthroplasty ACS NSQIP performance benchmarked against 472 participating sites.
| Total Hip Arthroplasty (472 sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 367 | 0.54% | 0.33% |
| 30 Day Morbidity | 367 | 2.18% | 4.19% |
| Cardiac | 367 | 0.27% | 0.42% |
| Pneumonia | 367 | 0.27% | 0.44% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 367 | 0.82% | 0.68% |
| Renal Failure | 366 | 0.55% | 0.41% |
| Urinary Tract Infection (UTI) | 367 | 0.54% | 0.79% |
| Surgical Site Infection (SSI) | 367 | 0.82% | 1.52% |
| Sepsis | 367 | 0.00% | 0.51% |
| C.diff Colitis | 367 | 0.27% | 0.07% |
| Unplanned Reoperation | 367 | 1.63% | 2.76% |
| Unplanned Readmission | 367 | 5.18% | 5.02% |
American College of Surgeons National Surgical Quality Improvement Program, 2024.
ACS NSQIP® Semiannual Report July 8, 2024, Chicago: American College of Surgeons.
